The Phase II KINETIC trial analysed KIN001 in Covid-19 patients in the hospital setting. Credit: NIAID / Flickr (Creative Commons).

Kinarus Therapeutics has announced plans to discontinue the Phase II KINETIC clinical trial of KIN001 in Covid-19 patients in the hospital setting.

The latest development comes after the independent Data and Safety Monitoring Board (DSMB) carried out a review of the study data and recommended the trial discontinuation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With a less than expected occurrence of the primary endpoint due to the evolution of the existing therapy landscape, the board decided that there exists a reduced chance to demonstrate a statistically significant benefit with an acceptable number of Covid-19 patients in the hospital. 

As a result, the DSMB recommended the discontinuation of the trial.

According to the safety results from the trial, a favourable profile was reported, with the occurrence of treatment-emergent adverse events (TEAEs) balanced between the trial arms.

See Also:

A combination of pamapimod and pioglitazone, KIN001 showed synergistic efficacy and enhanced response durability in preclinical models of several disease indications. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In cells infected with SARS-CoV-2, hindering p38 using the combination therapy showed to lower the replication of the virus, indicating synergistic activity compared to single therapies. 

KIN001 could also dull the overactive inflammatory response in ambulatory Covid-19 patients to lower disease duration, hospital admission, long-term morbidity, and the occurrence of long Covid.

Kinarus Therapeutics CEO Dr Alexander Bausch said: “The underlying scientific rationale for KIN001 remains intact as p38 MAP kinase, its key biological target, is well characterised and implicated in other indications via biological mechanisms that lead to a variety of chronic inflammatory diseases, including wet age-related macular degeneration (wAMD) and idiopathic pulmonary fibrosis (IPF). 

“The DSMB recommendation has no impact on our plans to develop KIN001 for treatment of wAMD and IPF or other indications.”

In August this year, the company dosed the first subject in the Phase II KINFAST trial of KIN001 in mild or moderate Covid-19 patients in an outpatient setting.